株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

Linzess (過敏性腸症候群治療薬) - 2023年までの予測と市場分析

Linzess (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023

発行 GlobalData 商品コード 325975
出版日 ページ情報 英文 45 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.18円で換算しております。

2016年12月31日まで 年末キャンペーン割引: GlobalData社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
Linzess (過敏性腸症候群治療薬) - 2023年までの予測と市場分析 Linzess (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023
出版日: 2014年12月31日 ページ情報: 英文 45 Pages
概要

当レポートでは、過敏性腸症候群の治療薬であるLinzessについて調査しており、過敏性腸症候群の概要や治療薬の競合動向、製品情報、売上予測などを提供しています。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要

  • 病因と病態生理学
    • 病因
    • 病態生理学
  • 分類
  • 症状
  • 予後
  • 生活の質 (QOL)

第4章 疾患の管理

  • 疾患と治療の概要
    • 診断
    • 治療ガイドラインと主な処方薬
    • 臨床診療

第5章 競合評価

  • 概要

第6章 Linzess (リナクロチド)

  • 概要
  • 有効性
  • 安全性
  • SWOT分析
  • 予測

第7章 付録

目次
Product Code: GDHC518DFR

Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function. Although IBS is not a life-threatening disorder, it has a considerable effect on patients' quality of life (QOL). In terms of volume, the IBS market is a large, albeit naive, one, with only a small number of pharmacotherapies indicated for the treatment of the disorder, and it is also characterized by significant unmet needs.

Linzess (linaclotide) is indicated for the treatment of IBS-C in adults. This product was initially discovered by Ironwood Pharmaceuticals, and its development and commercialization were supported by a series of licensing agreements with Forest in the US, Almirall in the EU, and Astellas in Japan. As of November 2014, Linzess was in Phase III of development as a potential treatment for IBS-C in Japan, and is therefore not currently available in this market.

Scope

  • Overview of IBS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Linzess including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Linzess for the top 7 countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, and Japan.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return.
  • Stay ahead of the competition by understanding the changing competitive landscape for IBS.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
  • Make more informed business decisions from insightful and in-depth analysis of Linzess performance.
  • Obtain sales forecast for Linzess from 2013-2023 in top 7 countries (the US, France, Germany, Italy, Spain, the UK, and Japan).

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Classification
  • 3.3. Symptoms
  • 3.4. Prognosis
  • 3.5. Quality of Life

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines and Leading Prescribed Drugs
    • 4.1.3. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview

6. Linzess (linaclotide)

  • 6.1. Overview
  • 6.2. Efficacy
  • 6.3. Safety

6.4. SWOT Analysis

  • 6.5. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Diagnosed IBS Patients
    • 7.4.2. General Pricing Assumptions
    • 7.4.3. Individual Drug Assumptions
    • 7.4.4. Generic Erosion
  • 7.5. Primary Research - KOLs Interviewed for This Report
  • 7.6. Primary Research - Prescriber Survey
  • 7.7. About the Authors
    • 7.7.1. Analyst
    • 7.7.2. Therapy Area Director
    • 7.7.3. Global Head of Healthcare
  • 7.8. About GlobalData
  • 7.9. Disclaimer

List of Tables

  • Table 1: Common Symptoms of IBS
  • Table 2: Summary of the Various Diagnostic Criteria Used for the Diagnosis of IBS
  • Table 3: Treatment Guidelines for IBS
  • Table 4: Leading Prescribed Drugs for IBS by Predominant Symptoms in the 7MM, 2014†
  • Table 5: Leading Branded Treatments for IBS, 2014
  • Table 6: Product Profile - Linzess
  • Table 7: Efficacy Responder Rates in Linzess' Two Placebo-Controlled IBS-C Trials: At Least Nine Out of 12 Weeks
  • Table 8: Efficacy Responder Rates in Linzess' Two Placebo-Controlled IBS-C Trials: At Least Six Out of 12 Weeks
  • Table 9: Safety of Linzess - Most Frequently Reported Adverse Events
  • Table 10: Linzess SWOT Analysis, 2014
  • Table 11: Global IBS Sales Forecasts ($m) for Linzess, 2013-2023
  • Table 12: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country

List of Figures

  • Figure 1: Summary of Pharmacotherapies Used to Treat IBS
Back to Top